[
  {
    "id": "doc:hc.adcetris",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Adcetris (brentuximab vedotin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.",
    "company": "Seagen Inc.",
    "drug_name_brand": "Adcetris",
    "drug_name_generic": "brentuximab vedotin",
    "first_published": null,
    "access_date": "2025-06-11",
    "organization_id": "hc",
    "publication_date": "2025-04-08",
    "url": "https://pdf.hres.ca/dpd_pm/00080158.PDF",
    "url_drug": "https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626",
    "application_number": null
  },
  {
    "id": "doc:hc.afinitor",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Afinitor (everolimus) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Afinitor",
    "drug_name_generic": "everolimus",
    "first_published": "2009-12-11",
    "access_date": "2025-06-11",
    "organization_id": "hc",
    "publication_date": "2021-11-30",
    "url": "https://pdf.hres.ca/dpd_pm/00063824.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511",
    "application_number": null
  },
  {
    "id": "doc:hc.akeega",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Akeega (abiraterone acetate and niraparib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Akeega (abiraterone acetate and niraparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078864.PDF. Revised March 2025. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Akeega",
    "drug_name_generic": "abiraterone acetate and niraparib",
    "first_published": "2023-06-07",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-03-12",
    "url": "https://pdf.hres.ca/dpd_pm/00078864.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102726",
    "application_number": null
  },
  {"id": "doc:hc.alecensaro",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Alecensaro (alectinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Alecensaro",
    "drug_name_generic": "alectinib",
    "first_published": "2016-09-29",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-03-11",
    "url": "https://pdf.hres.ca/dpd_pm/00078825.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.alunbrig",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Alunbrig (brigatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.",
    "company": "Takeda Canada Inc.",
    "drug_name_brand": "Alunbrig",
    "drug_name_generic": "brigatinib",
    "first_published": "2018-07-25",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2022-07-19",
    "url": "https://pdf.hres.ca/dpd_pm/00066731.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982",
    "application_number": null
  },
  {
    "id": "doc:hc.balversa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Balversa (erdafitinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Balversa",
    "drug_name_generic": "erdafitinib",
    "first_published": "2019-10-25",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-11-20",
    "url": "https://pdf.hres.ca/dpd_pm/00077812.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320",
    "application_number": null
  },
  {
    "id": "doc:hc.besponsa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Besponsa (inotuzumab ozogamicin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Besponsa",
    "drug_name_generic": "inotuzumab ozogamicin",
    "first_published": "2018-03-15",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-11-08",
    "url": "https://pdf.hres.ca/dpd_pm/00077730.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383",
    "application_number": null
  },
  {
    "id": "doc:hc.blincyto",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Blincyto (blinatumomab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.",
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Blincyto",
    "drug_name_generic": "blinatumomab",
    "first_published": "2015-12-22",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-12-27",
    "url": "https://pdf.hres.ca/dpd_pm/00078156.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642",
    "application_number": null
  },
  {
    "id": "doc:hc.bosulif",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Bosulif (bosutinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Bosulif",
    "drug_name_generic": "bosutinib",
    "first_published": "2014-03-07",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-07-12",
    "url": "https://pdf.hres.ca/dpd_pm/00076285.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368",
    "application_number": null
  },
  {
    "id": "doc:hc.braftovi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Braftovi (encorafenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Braftovi",
    "drug_name_generic": "encorafenib",
    "first_published": "2021-03-02",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-02-23",
    "url": "https://pdf.hres.ca/dpd_pm/00074711.PDF",
    "url_drug": null,
    "application_number": null
  },
  {
    "id": "doc:hc.cotellic",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Cotellic (cobimetinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Cotellic",
    "drug_name_generic": "cobimetinib",
    "first_published": "2016-02-22",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2023-03-24",
    "url": "https://pdf.hres.ca/dpd_pm/00070061.PDF",
    "url_drug": null,
    "application_number": null
  },
  {
     "id": "doc:hc.enhertu",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Enhertu (trastuzumab deruxtecan) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Enhertu",
    "drug_name_generic": "trastuzumab deruxtecan",
    "first_published": "2021-04-15",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-01-17",
    "url": "https://pdf.hres.ca/dpd_pm/00078361.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355",
    "application_number": null
  },
  {"id": "doc:hc.erbitux",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Erbitux (cetuximab) [product monograph]. HC.",
    "aliases": [],
    "citation": "ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.",
    "company": "ImClone LLC",
    "drug_name_brand": "Erbitux",
    "drug_name_generic": "cetuximab",
    "first_published": "2018-01-10",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2018-01-10",
    "url": "https://pdf.hres.ca/dpd_pm/00043071.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672",
    "application_number": null
  },
  {"id": "doc:hc.faslodex",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Faslodex (fulvestrant) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Faslodex",
    "drug_name_generic": "fulvestrant",
    "first_published": null,
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-11-15",
    "url": "https://pdf.hres.ca/dpd_pm/00053975.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981",
    "application_number": null
  },
  {"id": "doc:hc.giotrif",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Giotrif (afatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.",
    "company": "Boehringer Ingelheim (Canada) Ltd",
    "drug_name_brand": "Giotrif",
    "drug_name_generic": "afatinib",
    "first_published": null,
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2019-06-06",
    "url": "https://pdf.hres.ca/dpd_pm/00051644.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026",
    "application_number": null
  },
  {"id": "doc:hc.gleevec",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Gleevec (imatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Gleevec",
    "drug_name_generic": "imatinib",
    "first_published": "2001-09-19",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2021-08-31",
    "url": "https://pdf.hres.ca/dpd_pm/00067276.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824",
    "application_number": null
  },
  {"id": "doc:hc.herceptin",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Herceptin (trastuzumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Herceptin",
    "drug_name_generic": "trastuzumab",
    "first_published": "1999-08-13",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-05-02",
    "url": "https://pdf.hres.ca/dpd_pm/00080472.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277",
    "application_number": null
  },
  {"id": "doc:hc.ibrance",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Ibrance (palbociclib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Ibrance",
    "drug_name_generic": "palbociclib",
    "first_published": "2016-03-15",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-03-24",
    "url": "https://pdf.hres.ca/dpd_pm/00080011.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354",
    "application_number": null
  },
  {
    "id": "doc:hc.iclusig",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Iclusig (ponatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.",
    "company": "Takeda Pharmaceuticals U.S.A., Inc.",
    "drug_name_brand": "Iclusig",
    "drug_name_generic": "ponatinib",
    "first_published": "2015-03-31",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-02-24",
    "url": "https://pdf.hres.ca/dpd_pm/00078669.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168",
    "application_number": null
  },
  {"id": "doc:hc.imfinzi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Imfinzi (durvalumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Imfinzi",
    "drug_name_generic": "durvalumab",
    "first_published": "2017-11-03",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-04-10",
    "url": "https://pdf.hres.ca/dpd_pm/00080178.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736",
    "application_number": null
  },
  {"id": "doc:hc.iressa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Iressa (gefitinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Iressa",
    "drug_name_generic": "gefitinib",
    "first_published": "2003-12-17",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2021-03-31",
    "url": "https://pdf.hres.ca/dpd_pm/00060650.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040",
    "application_number": null
  },
  {"id": "doc:hc.itovebi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Itovebi (inavolisib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Itovebi",
    "drug_name_generic": "inavolisib",
    "first_published": "2025-02-14",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-02-14",
    "url": "https://pdf.hres.ca/dpd_pm/00078611.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427",
    "application_number": null
  },
  {"id": "doc:hc.jemperli",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Jemperli (dostarlimab) [product monograph]. HC.",
    "aliases": [],
    "citation": "GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.",
    "company": "GlaxoSmithKline Inc.",
    "drug_name_brand": "Jemperli",
    "drug_name_generic": "dostarlimab",
    "first_published": "2025-04-06",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-04-16",
    "url": "https://pdf.hres.ca/dpd_pm/00080289.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252",
    "application_number": null
  },
  {"id": "doc:hc.kadcyla",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Kadcyla",
    "drug_name_generic": "ado-trastuzumab emtansine",
    "first_published": "2013-09-11",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2022-10-13",
    "url": "https://pdf.hres.ca/dpd_pm/00067729.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698",
    "application_number": null
  },
  {"id": "doc:hc.keytruda",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Keytruda (pembrolizumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.",
    "company": "Merck Canada Inc.",
    "drug_name_brand": "Keytruda",
    "drug_name_generic": "pembrolizumab",
    "first_published": "2025-04-11",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-04-11",
    "url": "https://pdf.hres.ca/dpd_pm/00080285.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388",
    "application_number": null
  },
  {"id": "doc:hc.kisqali",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Kisqali (ribociclib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Kisqali",
    "drug_name_generic": "ribociclib",
    "first_published": "2018-03-02",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-05-31",
    "url": "https://pdf.hres.ca/dpd_pm/00075798.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.lazcluze",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Lazcluze (lazertinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Lazcluze",
    "drug_name_generic": "lazertinib",
    "first_published": "2025-03-06",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-03-06",
    "url": "https://pdf.hres.ca/dpd_pm/00078792.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468",
    "application_number": null
  },
  {"id": "doc:hc.libtayo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Libtayo (cemiplimab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.",
    "company": "Regeneron Canada Company",
    "drug_name_brand": "Libtayo",
    "drug_name_generic": "cemiplimab",
    "first_published": "2019-04-10",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-01-30",
    "url": "https://pdf.hres.ca/dpd_pm/00078455.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728",
    "application_number": null
  },

  {"id": "doc:hc.lorbrena",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Lorbrena (lorlatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Lorbrena",
    "drug_name_generic": "lorlatinib",
    "first_published": "2019-02-20",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-10-28",
    "url": "https://pdf.hres.ca/dpd_pm/00077541.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619",
    "application_number": null
  },
  {"id": "doc:hc.lumakras",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Lumakras (sotorasib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.",
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Lumakras",
    "drug_name_generic": "sotorasib",
    "first_published": "2021-09-09",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-03-04",
    "url": "https://pdf.hres.ca/dpd_pm/00078781.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931",
    "application_number": null
  },
  {"id": "doc:hc.lynparza",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Lynparza (olaparib) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Lynparza",
    "drug_name_generic": "olaparib",
    "first_published": "2025-04-29",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-04-29",
    "url": "https://pdf.hres.ca/dpd_pm/00080379.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554",
    "application_number": null
  },
  {"id": "doc:hc.mekinist",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Mekinist (trametinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Mekinist",
    "drug_name_generic": "trametinib",
    "first_published": "2013-07-18",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-12-05",
    "url": "https://pdf.hres.ca/dpd_pm/00077955.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431",
    "application_number": null
  },
  {"id": "doc:hc.mektovi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Mektovi (binimetinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Mektovi",
    "drug_name_generic": "binimetinib",
    "first_published": "2021-03-02",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-03-02",
    "url": "https://pdf.hres.ca/dpd_pm/00060288.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.mylotarg",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Mylotarg (gemtuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00069427.PDF. Revised February 2023. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Mylotarg",
    "drug_name_generic": "gemtuzumab ozogamicin",
    "first_published": "2019-11-28",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-02-02",
    "url": "https://pdf.hres.ca/dpd_pm/00069427.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98440",
    "application_number": null
  },
  {
    "id": "doc:hc.nerlynx",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Nerlynx (neratinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.",
    "company": "Knight Therapeutics Inc.",
    "drug_name_brand": "Nerlynx",
    "drug_name_generic": "neratinib",
    "first_published": "2019-07-15",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-07-16",
    "url": "https://pdf.hres.ca/dpd_pm/00062158.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.opdivo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Opdivo (nivolumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.",
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Opdivo",
    "drug_name_generic": "nivolumab",
    "first_published": "2015-09-25",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-06-28",
    "url": "https://pdf.hres.ca/dpd_pm/00076152.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204",
    "application_number": null
  },
  {"id": "doc:hc.pemazyre",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Pemazyre (pemigatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.",
    "company": "Incyte Corporation",
    "drug_name_brand": "Pemazyre",
    "drug_name_generic": "pemigatinib",
    "first_published": "2021-09-09",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-09-08",
    "url": "https://pdf.hres.ca/dpd_pm/00062968.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917",
    "application_number": null
  },
  {"id": "doc:hc.perjeta",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Perjeta (pertuzumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Perjeta",
    "drug_name_generic": "pertuzumab",
    "first_published": "2013-04-12",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2013-04-12",
    "url": "https://pdf.hres.ca/dpd_pm/00060125.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984",
    "application_number": null
  },
  {"id": "doc:hc.phesgo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Phesgo",
    "drug_name_generic": "pertuzumab and trastuzumab",
    "first_published": "2021-03-01",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2022-01-05",
    "url": "https://pdf.hres.ca/dpd_pm/00064237.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216",
    "application_number": null
  },
  {"id": "doc:hc.piqray",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Piqray (alpelisib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Piqray (alpelisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076641.PDF. Revised August 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Piqray",
    "drug_name_generic": "alpelisib",
    "first_published": "2020-03-11",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-08-12",
    "url": "https://pdf.hres.ca/dpd_pm/00076641.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98692",
    "application_number": null
  },
  {"id": "doc:hc.retevmo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Retevmo (selpercatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.",
    "company": "Loxo Oncology Inc.",
    "drug_name_brand": "Retevmo",
    "drug_name_generic": "selpercatinib",
    "first_published": "2021-06-11",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-01-10",
    "url": "https://pdf.hres.ca/dpd_pm/00078253.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625",
    "application_number": null
  },
  {"id": "doc:hc.revlimid",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Revlimid (lenalidomide) [product monograph]. HC.",
    "aliases": [],
    "citation": "Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.",
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Revlimid",
    "drug_name_generic": "lenalidomide",
    "first_published": "2024-02-09",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-02-09",
    "url": "https://pdf.hres.ca/dpd_pm/00074535.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016",
    "application_number": null
  },
  {"id": "doc:hc.rituxan",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Rituxan (rituximab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Rituxan",
    "drug_name_generic": "rituximab",
    "first_published": "2000-03-17",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-06-02",
    "url": "https://pdf.hres.ca/dpd_pm/00071131.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597",
    "application_number": null
  },
  {"id": "doc:hc.rozlytrek",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Rozlytrek (entrectinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Rozlytrek",
    "drug_name_generic": "entrectinib",
    "first_published": "2020-02-07",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-11-09",
    "url": "https://pdf.hres.ca/dpd_pm/00073345.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496",
    "application_number": null
  },
  {"id": "doc:hc.rybrevant",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Rybrevant (amivantamab-vmjw) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Rybrevant",
    "drug_name_generic": "amivantamab-vmjw",
    "first_published": "2022-03-30",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-01-13",
    "url": "https://pdf.hres.ca/dpd_pm/00078295.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529",
    "application_number": null
  },
  {"id": "doc:hc.rydapt",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Rydapt (midostaurin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Rydapt",
    "drug_name_generic": "midostaurin",
    "first_published": "2017-07-21",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-03-31",
    "url": "https://pdf.hres.ca/dpd_pm/00070168.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.scemblix",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Scemblix (asciminib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Scemblix (asciminib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076300.PDF. Revised July 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc",
    "drug_name_brand": "Scemblix",
    "drug_name_generic": "asciminib",
    "first_published": "2022-06-21",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-07-12",
    "url": "https://pdf.hres.ca/dpd_pm/00076300.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101756",
    "application_number": null
  },
  {"id": "doc:hc.sprycel",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Sprycel (dasatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.",
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Sprycel",
    "drug_name_generic": "dasatinib",
    "first_published": "2007-03-22",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-11-03",
    "url": "https://pdf.hres.ca/dpd_pm/00063441.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850",
    "application_number": null
  },
  {"id": "doc:hc.tabrecta",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tabrecta (capmatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tabrecta",
    "drug_name_generic": "capmatinib",
    "first_published": "2022-05-19",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-06-26",
    "url": "https://pdf.hres.ca/dpd_pm/00071417.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646",
    "application_number": null
  },
  {"id": "doc:hc.tafinlar",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tafinlar (dabrafenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tafinlar",
    "drug_name_generic": "dabrafenib",
    "first_published": "2013-08-23",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-12-05",
    "url": "https://pdf.hres.ca/dpd_pm/00077956.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429",
    "application_number": null
  },
  {"id": "doc:hc.tagrisso",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tagrisso (osimertinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Tagrisso",
    "drug_name_generic": "osimertinib",
    "first_published": "2016-07-05",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-04-23",
    "url": "https://pdf.hres.ca/dpd_pm/00080336.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310",
    "application_number": null
  },
  {"id": "doc:hc.talzenna",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Talzenna (talazoparib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Talzenna (talazoparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078463.PDF. Revised January 2025. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Talzenna",
    "drug_name_generic": "talazoparib",
    "first_published": "2020-09-30",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-01-30",
    "url": "https://pdf.hres.ca/dpd_pm/00078463.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98204",
    "application_number": null
  },
  {"id": "doc:hc.tasigna",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tasigna (nilotinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tasigna",
    "drug_name_generic": "nilotinib",
    "first_published": "2008-09-30",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-07-17",
    "url": "https://pdf.hres.ca/dpd_pm/00076372.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138",
    "application_number": null
  },
  {"id": "doc:hc.tecentriq",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tecentriq (atezolizumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Tecentriq",
    "drug_name_generic": "atezolizumab",
    "first_published": "2017-04-12",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-01-09",
    "url": "https://pdf.hres.ca/dpd_pm/00078266.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089",
    "application_number": null
  },
  {"id": "doc:hc.tepmetko",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tepmetko (tepotinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.",
    "company": "EMD Serono, a Division of EMD Inc., Canada",
    "drug_name_brand": "Tepmetko",
    "drug_name_generic": "tepotinib",
    "first_published": "2021-05-27",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-03-04",
    "url": "https://pdf.hres.ca/dpd_pm/00074821.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.tibsovo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tibsovo (ivosidenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.",
    "company": "Servier Canada Inc.",
    "drug_name_brand": "Tibsovo",
    "drug_name_generic": "ivosidenib",
    "first_published": "2024-07-19",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-07-19",
    "url": "https://pdf.hres.ca/dpd_pm/00076398.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.trodelvy",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Trodelvy (sacituzumab govitecan) [product monograph]. HC.",
    "aliases": [],
    "citation": "Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.",
    "company": "Gilead Sciences Canada, Inc.",
    "drug_name_brand": "Trodelvy",
    "drug_name_generic": "sacituzumab govitecan",
    "first_published": "2025-05-14",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-05-14",
    "url": "https://pdf.hres.ca/dpd_pm/00080546.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997",
    "application_number": null
  },
  {"id": "doc:hc.truqap",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Truqap (capivasertib) [product monograph]. HC.",
    "aliases": [],
    "citation": "AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.",
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Truqap",
    "drug_name_generic": "capivasertib",
    "first_published": "2024-01-24",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2025-01-03",
    "url": "https://pdf.hres.ca/dpd_pm/00078178.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334",
    "application_number": null
  },
  {"id": "doc:hc.tukysa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tukysa (tucatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Seagen Inc. Tukysa (tucatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062119.PDF. Revised July 2021. Accessed June 2025.",
    "company": "Seagen Inc.",
    "drug_name_brand": "Tukysa",
    "drug_name_generic": "tucatinib",
    "first_published": "2020-06-03",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-07-08",
    "url": "https://pdf.hres.ca/dpd_pm/00062119.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98955",
    "application_number": null
  },
  {"id": "doc:hc.tykerb",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Tykerb (lapatinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Tykerb (lapatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064944.PDF. Revised March 2022. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tykerb",
    "drug_name_generic": "lapatinib",
    "first_published": "2009-01-05",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2022-03-02",
    "url": "https://pdf.hres.ca/dpd_pm/00064944.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.vectibix",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Vectibix (panitumumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.",
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Vectibix",
    "drug_name_generic": "panitumumab",
    "first_published": "2008-04-03",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2021-10-25",
    "url": "https://pdf.hres.ca/dpd_pm/00063326.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79412",
    "application_number": null
  },
  {"id": "doc:hc.verzenio",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": " Verzenio (abemaciclib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.",
    "company": "Eli Lilly Canada Inc.",
    "drug_name_brand": "Verzenio",
    "drug_name_generic": "abemaciclib",
    "first_published": "2019-04-04",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-12-01",
    "url": "https://pdf.hres.ca/dpd_pm/00073683.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723",
    "application_number": null
  },
  {"id": "doc:hc.vitrakvi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Vitrakvi (larotrectinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.",
    "company": "Bayer Inc.",
    "drug_name_brand": "Vitrakvi",
    "drug_name_generic": "larotrectinib",
    "first_published": "2019-07-04",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-09-03",
    "url": "https://pdf.hres.ca/dpd_pm/00076917.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037",
    "application_number": null
  },
  {"id": "doc:hc.voranigo",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Voranigo (vorasidenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.",
    "company": "Servier Canada Inc.",
    "drug_name_brand": "Voranigo",
    "drug_name_generic": "vorasidenib",
    "first_published": "2024-08-27",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-08-27",
    "url": "https://pdf.hres.ca/dpd_pm/00076841.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996",
    "application_number": null
  },
  {"id": "doc:hc.vyloy",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Vyloy (zolbetuximab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Astellas Pharma Canada, Inc. Vyloy (zolbetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078035.PDF. Published December 2024. Accessed June 2025.",
    "company": "Astellas Pharma Canada, Inc.",
    "drug_name_brand": "Vyloy",
    "drug_name_generic": "zolbetuximab",
    "first_published": "2024-12-13",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2024-12-13",
    "url": "https://pdf.hres.ca/dpd_pm/00078035.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104288",
    "application_number": null
  },
  {"id": "doc:hc.xalkori",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Xalkori (crizotinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Xalkori",
    "drug_name_generic": "crizotinib",
    "first_published": "2012-04-25",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-04-17",
    "url": "https://pdf.hres.ca/dpd_pm/00070448.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999",
    "application_number": null
  },
  {
    "id": "doc:hc.xospata",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Xospata (gilteritinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.",
    "company": "Astellas Pharma Canada, Inc.",
    "drug_name_brand": "Xospata",
    "drug_name_generic": "gilteritinib",
    "first_published": "2019-12-23",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2022-01-04",
    "url": "https://pdf.hres.ca/dpd_pm/00064190.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.yervoy",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Yervoy (ipilimumab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.",
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Yervoy",
    "drug_name_generic": "ipilimumab",
    "first_published": "2012-02-01",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2023-12-07",
    "url": "https://pdf.hres.ca/dpd_pm/00074279.PDF",
    "url_drug":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525",
    "application_number": null
  },
  {"id": "doc:hc.zelboraf",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Zelboraf (vemurafenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.",
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Zelboraf",
    "drug_name_generic": "vemurafenib",
    "first_published": null,
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2019-12-10",
    "url": "https://pdf.hres.ca/dpd_pm/00054278.PDF",
    "url_drug": null,
    "application_number": null
  },
  {"id": "doc:hc.zykadia",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Zykadia (ceritinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Zykadia",
    "drug_name_generic": "ceritinib",
    "first_published": "2015-03-27",
    "access_date": "2025-06-13",
    "organization_id": "hc",
    "publication_date": "2022-02-25",
    "url": "https://pdf.hres.ca/dpd_pm/00064867.PDF",
    "url_drug":null,
    "application_number": null
  }
]
